Drugs / polyglutamate camptothecin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00059917 | Jan 2003 → May 2005 | cancer of unknown primary site | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | polyglutamate camptothecin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00059917 ↗ |
| Known as | CT-2106 | “Patients receive polyglutamate camptothecin (CT-2106) IV over 10 minutes on day 1.” NCT00059917 ↗ |
| Route | Intravenous | “Patients receive polyglutamate camptothecin (CT-2106) IV over 10 minutes on day 1.” NCT00059917 ↗ |